Medizinische Klinik
KKE Translationale Immunologie

500
501
502
503
560

Adresse: Otfried-Müller-Str. 10
72076 Tübingen


Sekretariat

frontend.sr-only_#{element.icon}: 07071 29-83275


frontend.sr-only_#{element.icon}: 07071 29-4391


frontend.sr-only_#{element.icon}: Sabrina.augstein@med.uni-tuebingen.de


Peptid-basierte Immuntherapie

Scientific focus

In recent years the breakthrough clinical success of T-cell based immunotherapy approaches including advances in allogeneic stem cell transplantation, checkpoint inhibitors, CAR T cells, bispecific antibodies and adoptive T-cell transfer have revolutionized treatment of several malignancies. However, still some patients do not respond to available therapeutic strategies at all, others for limited time only. Remaining challenges to augment efficacy of T cell-based immunotherapy are particularly to improve specificity and increase the frequency of anti-tumor immune responses, to reduce toxicity and to expand the spectrum of targetable cancer entities. A rational and promising approach to achieve this goal is peptide-based immunotherapy, which represents a low side-effect approach relying on specific immune recognition of tumor-associated HLA (human leucocyte antigen) presented peptides.

Our research group works on the direct mass spectrometric analysis of these HLA presented peptides, the so called immunopeptidome of different tumors with the aim to (I) identify and characterize novel tumor-associated HLA-presented antigens, to (II) evaluate the influence of different cancer drugs on the immunopeptidome of tumor cells and to (III) translate these experimental results in a final step into clinical peptide-based immunotherapy concepts for cancer patients. For chronic lymphocytic leukemia (CLL) this goal has already been achieved: The first multicenter patient-individualized peptide vaccination study for the treatment of CLL patients (iVAC-CLL01, NCT02802943) has been established and is successfully recruiting since October 2016. 

Contact

frontend.sr-only_#{element.contextual_1.children.icon}: PD Dr. med. Juliane Walz Group Leader


More about the person

Laboratory

frontend.sr-only_#{element.contextual_1.children.icon}: +49 7071-29 78685



Team

Awards and prizes

  • 2018„Posterpreis“ DGHO Wien
  • 2017“Posterpreis“ of the University Tübingen, research colloquium
  • 2016Young Investigator Award DGHO Leipzig
  • 2015„Posterpreis“ DGHO Basel
    „Württembergischer Krebspreis“, junior award
  • 2014Abstract Achievement Award American Society of Hematology
  • 2013Abstract Achievement Award American Society of Hematology
  • 2012Abstract Achievement Award American Society of Hematology
  • 2011Promotionspreis“ of the Eberhard Karls University Tübingen
    „Ludolf Krehl Promotionspreis“ of the Süddeutschen Gesellschaft für Innere Medizin

Selected publications

  • Bilich T, Nelde A, Bichmann L, Roerden M, Salih HR, Kowalewski DJ, Schuster H, Tsou CC, Marcu A, Neidert MC, Lübke M, Rieth J, Schemionek M, Brümmendorf TH, Vucinic V, Niederwieser D, Bauer J, Märklin M, Peper JK, Klein R, Kohlbacher O, Kanz L, Rammensee HG, Stevanović S, Walz JS (2018). The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. Blood. 2018 Dec 10. pii: blood-2018-07-866830. [Epub ahead of print]
  • Neidert MC, Kowalewski DJ, Silginer M, Kapolou K, Backert L, Peper JK Marcu A, Freudenmann LK, Wang S, Walz JS, Wolpert F, Rammensee HG, Henschler R, Lamszus K, Westphal M, Roth P, Regli L, Stevanovic S, Weller M, Eisele, G (2018). The natural HLA ligandome of glioblastoma stem-like cells: Antigen discovery for T cell based immunotherapy. Acta Neuropathol. 2018 Jun;135(6):923-938
  • Nelde A, Kowalewski DJ, Backert L, Schuster H, Werner JO, Klein R, Kohlbacher O, Kanz L, Salih HR, Rammensee HG, Stevanović S, Walz JS (2018). HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell based immunotherapy. Oncoimmunology. 2018 Feb 14;7(4):e1316438.
  • Walz JS, Kowalewski DJ, Backer L, Nelde A, Kohlbacher O, Weide B, Kanz L, Salih HR, Rammensee HG, Stevanović S (2018). Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers. Leuk Lymphoma. 2018 Jan 3:1-10.
  • Heidenreich F, Rücker-Braun E, Walz JS, Eugster A, Kühn D, Dietz S, Nelde A, Tunger A, Wehner R, Link CS, Middeke JM, Stolzel F, Tonn T, Stevanovic S, Rammensee HG, Bonifacio E, Bachmann M, Zeis M, Ehninger G, Bornhäuser M, Schetelig J, Schmitz M (2017). Mass spectrometry-based identification of a naturally presented receptor tyrosine kinase-like orphan receptor 1-derived epitope recognized by CD8+ cytotoxic T cells. Haematologica. 2017 Nov;102(11):e460-e464.


Funding

Cookie Einstellungen
Bitte treffen Sie eine Auswahl um fortzufahren.
Weitere Informationen zu den Auswirkungen Ihrer Auswahl finden Sie unter Hilfe.
 
Um fortfahren zu können, müssen Sie eine Cookie-Auswahl treffen.

Cookies zulassen:
Wir setzen das Analysetool Google Analytics ein, um Besucher-Informationen wie z.B. Browser, Land, oder die Dauer, wie lange ein Benutzer auf unserer Seite verweilt, zu messen. Ihre IP-Adresse wird anonymisiert übertragen, die Verbindung zu Google ist verschlüsselt.

Nur notwendige Cookies zulassen:
Wir verzichten auf den Einsatz von Analysetools. Es werden jedoch technisch notwendige Cookies, die eine reibungslose Navigation und Nutzung der Webseite ermöglichen, gesetzt (beispielsweise den Zugang zum zugangsbeschränkten Bereich erlauben).

Sie können Ihre Cookie-Einstellung jederzeit auf der Seite Datenschutzerklärung ändern. Zum Impressum.

Zurück

Cookies zulassen Nur notwendige Cookies zulassen